R&D | January 16, 2026
Redesigned brain receptor drugs show promise for depression
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
The approval is supported by data from three pivotal clinical trials
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
